ArticleRSC advances2022
Cisplatin and oleanolic acid Co-loaded pH-sensitive CaCO
Article in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 38 citations in OpenAlex.
- Selected Pentacyclic Triterpenoids and Their Derivatives as Biologically Active Compounds.Molecules (Basel, Switzerland) · 2025Review
- Review
- Unlocking the Potential of Oleanolic Acid: Integrating Pharmacological Insights and Advancements in Delivery Systems.Pharmaceutics · 2024Review
- Co-delivery of paclitaxel and curcumin loaded solid lipid nanoparticles for improved targeting of lung cancer:Heliyon · 2024Article
- Calcium Carbonate-Based Nanoplatforms for Cancer Therapeutics: Current State of Art and Future Breakthroughs.ACS omega · 2024Review
- Application of temperature-sensitive liquid embolic agent loaded with oxaliplatin in the TACE procedure for rabbit VX2 gastric cancer.Drug delivery and translational research · 2024Article
- Recent Developments in CaCOPharmaceutics · 2024Review
- Layer-by-Layer Nanoparticles for Calcium Overload in situ Enhanced Reactive Oxygen Oncotherapy.International journal of nanomedicine · 2024Article
- Research Progress on the Synergistic Anti-Tumor Effect of Natural Anti-Tumor Components of Chinese Herbal Medicine Combined with Chemotherapy Drugs.Pharmaceuticals (Basel, Switzerland) · 2023Review
- A detailed insight of the tumor targeting using nanocarrier drug delivery system.Drug delivery · 2023Review
- Design, synthesis, and biological evaluation of new arjunolic acid derivatives as anticancer agents.RSC medicinal chemistry · 2023Article
- Research progress of calcium carbonate nanomaterials in cancer therapy: challenge and opportunity.Frontiers in bioengineering and biotechnology · 2023Review
- Novel Tumor-Targeted Self-Nanostructured and Compartmentalized Water-in-Oil-in-Water Polyurethane-Polyurea Nanocapsules for Cancer Theragnosis.Pharmaceutics · 2022Article
- Ameliorative impacts of polymeric and metallic nanoparticles on cisplatin-induced nephrotoxicity: a 2011-2022 review.Journal of nanobiotechnology · 2022Review
- Development of nanocubosomes co-loaded with dual anticancer agents curcumin and temozolomide for effective Colon cancer therapy.Drug delivery · 2022Article
- Transdermal delivery of allopurinol-loaded nanostructured lipid carrier in the treatment of gout.BMC pharmacology & toxicology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite being one of the most potent anticancer agents, cisplatin (CDDP) clinical usage is limited owing to the acquired resistance and severe adverse effects including nephrotoxicity. The current work has offered a unique approach by designing a pH-sensitive calcium carbonate drug delivery system for CDDP and oleanolic acid (OA) co-delivery, with an enhanced tumor efficacy and reduced unwanted effects. Micro emulsion method was employed to generate calcium carbonate cores (CDDP encapsulated) followed by lipid coating along with the OA loading resulting in the generation of lipid-coated cisplatin/oleanolic acid calcium carbonate nanoparticles (CDDP/OA-LCC NPs).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.